BioLineRx Ltd.
BLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,940 | $4,800 | $0 | $0 |
| % Growth | 502.9% | – | – | – |
| Cost of Goods Sold | $9,263 | $3,692 | $0 | $0 |
| Gross Profit | $19,677 | $1,108 | $0 | $0 |
| % Margin | 68% | 23.1% | – | – |
| R&D Expenses | $9,149 | $12,519 | $17,629 | $19,466 |
| G&A Expenses | $18,460 | $16,637 | $5,066 | $4,266 |
| SG&A Expenses | $28,540 | $31,230 | $11,528 | $5,269 |
| Sales & Mktg Exp. | $10,080 | $14,593 | $6,462 | $1,003 |
| Other Operating Expenses | $2,396 | $7,053 | $0 | $42 |
| Operating Expenses | $40,085 | $50,802 | $29,157 | $24,777 |
| Operating Income | -$20,408 | -$49,694 | -$29,157 | -$24,777 |
| % Margin | -70.5% | -1,035.3% | – | – |
| Other Income/Exp. Net | $11,187 | -$10,920 | $4,206 | -$2,277 |
| Pre-Tax Income | -$9,221 | -$60,614 | -$24,951 | -$27,054 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,221 | -$60,614 | -$24,951 | -$27,054 |
| % Margin | -31.9% | -1,262.8% | – | – |
| EPS | -0.12 | -0.94 | -0.48 | -0.61 |
| % Growth | 87.2% | -95.8% | 21.3% | – |
| EPS Diluted | -0.12 | -0.94 | -0.48 | -0.61 |
| Weighted Avg Shares Out | 79,874 | 64,224 | 51,597 | 44,196 |
| Weighted Avg Shares Out Dil | 79,874 | 64,224 | 51,597 | 44,196 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,829 | $2,007 | $694 | $559 |
| Interest Expense | $9,162 | $2,169 | $2,158 | $984 |
| Depreciation & Amortization | $4,065 | $1,384 | $654 | $703 |
| EBITDA | $3,918 | -$57,086 | -$28,503 | -$24,074 |
| % Margin | 13.5% | -1,189.3% | – | – |